Establishment of A New Strategy for the Treatment of Atherosclerosis by Activating Reverse Cholesterol Transport
Description: We identified GPI-anchored type HDL- and apo A-I- binding protein with molecular weight of 80 KDa from human monocyte-derived macrophages by ligand blotting analysis.Phospholipase C (PI-PLC) treatment of the cells decreased both the binding of HDL to and subsequent cholesterol efflux from the cells. From the cultured human macrophages, the 80 KDa HDL/apo A-I binding protein was purified with HDL-affmity column. The protein was digested with endopeptidase and the resultant fragments were sequenced for the determination of internal amino acid sequences. Two parts of 1 1 amino acid sequences completely matched those of moesin. Treatment of macrophages with anti-human moesin antibody blocked the binding of HDL and apo A-I as well as HDL- and apo A-I-mediated cholesterol efflux from human macrophages. Flowcytometric, immunohistochemical and two-dimensional immunoblotting analyzes using anti-moesin antibodies revealed that the moesin-like, GPI-anchored type HDL-binding protein is expressed on the cell surface and exclusively on monocyte-derived macrophages. Thus, we demonstrate that a moesin-like protein expressed on cell surface plays a crucial role in cholesterol efflux from macrophages as one of the specific HDL/apo A-I binding proteins.
Amount: ¥3,900,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Investigator: Naohiko SAKAI (lead)
Institutions: The University of Osaka, Osaka University Graduate School of medicine
Subfield: Biochemistry
Domain: Life Sciences
Funded outputs count: 1
Funder award ID: 12670666
OpenAlex ID: G1948064044
